Gleason score abnormality - Causes, Treatment & When to See a Doctor

What is Gleason score abnormality?

The Gleason score is a pathological grading system used to evaluate how aggressive prostate cancer cells look under a microscope. A “Gleason score abnormality” refers to any result that falls outside the typical low‑grade range (6 or below) and suggests a higher‑grade, more aggressive tumor (scores 7–10). The score is derived from adding the two most common Gleason patterns observed in a biopsy specimen, each rated from 1 (well‑differentiated) to 5 (poorly differentiated). For example, a Gleason 3 + 4 = 7 indicates that pattern 3 predominates, whereas 4 + 3 = 7 means the higher‑grade pattern is more common. An abnormal score alerts clinicians that the cancer may grow faster, spread earlier, and may require more intensive treatment.

Because the Gleason score directly influences treatment decisions and prognosis, understanding what constitutes an abnormal result is essential for patients and health‑care providers alike.

Common Causes

While the Gleason score itself is not a disease, certain conditions and factors can lead to a higher (abnormal) Gleason score when prostate cancer is present. The most common contributors include:

• High‑grade prostate adenocarcinoma: The primary cause of an elevated Gleason score.
• Genetic mutations: BRCA1/2, HOXB13, and DNA mismatch‑repair defects increase the likelihood of aggressive tumors.
• Age: Men over 65 have a higher chance of developing high‑grade disease.
• Family history of prostate cancer: A first‑degree relative with prostate cancer raises risk of aggressive forms.
• African‑American ancestry: This population experiences higher rates of high‑grade prostate cancer.
• Hormonal imbalance: Elevated testosterone or androgen‑receptor signaling can promote aggressive tumor growth.
• Exposure to carcinogens: Occupational exposure to pesticides, heavy metals, or Agent Orange has been linked to higher Gleason grades.
• Inflammatory prostatitis: Chronic inflammation may create an environment conducive to more aggressive carcinoma.
• Obesity and metabolic syndrome: Insulin resistance and excess adipose tissue have been associated with higher Gleason scores.
• Prior radiation therapy to the pelvis: Radiation‑induced DNA damage can give rise to high‑grade secondary prostate cancers.

Associated Symptoms

Prostate cancer, especially when it carries an abnormal Gleason score, may present with a combination of urinary, sexual, and systemic symptoms. Not every man will experience all of these, but the following are the most frequently reported:

• Difficulty starting the urine stream (hesitancy)
• Weak or intermittent urine flow
• Frequent urination, especially at night (nocturia)
• Feeling of incomplete bladder emptying
• Blood in the urine (hematuria) or semen
• Painful ejaculation
• Persistent pain in the lower back, hips, or pelvis (possible sign of metastasis)
• Unexplained weight loss or fatigue
• Erectile dysfunction that develops without a clear cause
• Swelling in the legs or feet (if cancer blocks lymphatic drainage)

When to See a Doctor

Early evaluation can prevent a low‑grade cancer from progressing to a high‑grade, life‑threatening disease. Seek medical attention promptly if you notice any of the following:

• New or worsening urinary obstruction (weak stream, hesitancy, retention)
• Blood in urine or semen
• Painful ejaculation or persistent perineal pain
• Unexplained weight loss, fatigue, or night sweats
• Back, hip, or pelvic pain that does not improve with rest
• Any abnormal result on a prostate‑specific antigen (PSA) test, especially if PSA > 4 ng/mL or rising rapidly
• Previous diagnosis of prostate cancer with a Gleason score ≥ 7 and new symptoms

Even in the absence of symptoms, men at higher risk (family history, African‑American ethnicity, age > 50) should discuss regular screening with their primary‑care physician.

Diagnosis

When a clinician suspects prostate cancer or receives an abnormal Gleason score from a prior biopsy, a systematic work‑up is undertaken:

1. Prostate‑specific antigen (PSA) testing

Serum PSA is measured; a level > 4 ng/mL or a rapid rise (≥ 0.75 ng/mL per year) often triggers further testing.

2. Digital rectal examination (DRE)

The physician feels the prostate through the rectal wall to detect nodules, asymmetry, or firmness.

3. Multiparametric MRI (mpMRI)

Provides detailed imaging of the prostate, helping to locate suspicious lesions and guide biopsies.

4. Prostate biopsy

• Systematic TRUS‑guided biopsy: 10‑12 cores taken from standard zones.
• Targeted biopsy: Uses mpMRI fusion to sample specific lesions, improving detection of high‑grade cancer.

5. Pathology and Gleason grading

Expert genitourinary pathologists assign Gleason patterns to each core, calculate the total Gleason score, and may add a Grade Group (1‑5) per the 2014 ISUP consensus.

6. Staging investigations (if high Gleason score)

• Bone scan (technetium‑99m) to look for skeletal metastases.
• CT or PET/CT (e.g., PSMA PET) for lymph‑node or distant spread.

7. Molecular testing (optional)

Genomic classifiers (e.g., Decipher, Oncotype DX) can provide additional risk stratification for treatment planning.

Treatment Options

Therapy is individualized based on Gleason score, tumor stage, PSA level, patient age, comorbidities, and personal preferences. Options include both medical interventions and supportive measures you can undertake at home.

1. Active Surveillance (AS)

Appropriate for low‑risk disease (Gleason 6, PSA < 10 ng/mL, stage T1‑T2a). Involves regular PSA tests, DRE, and repeat biopsies every 1–2 years. Though not a “treatment,” AS postpones invasive therapy while monitoring for progression.

2. Radical Prostatectomy

Removal of the entire prostate gland, often with nerve-sparing techniques to preserve erectile function. Laparoscopic or robot‑assisted approaches reduce recovery time.

3. Radiation Therapy

• External beam radiation therapy (EBRT): Intensity‑modulated or image‑guided radiation.
• Brachytherapy: Permanent implantation of radioactive seeds (I‑125 or Pd‑103).
• Combination of EBRT + brachytherapy is sometimes used for Gleason ≥ 8 disease.

4. Hormone (Androgen Deprivation) Therapy (ADT)

Drugs such as leuprolide, goserelin, or oral antiandrogens lower testosterone, slowing tumor growth. ADT is often combined with radiation for high‑grade cancers.

5. Chemotherapy

Docetaxel or cabazitaxel may be added for metastatic or castration‑resistant prostate cancer (CRPC) with high Gleason scores.

6. Novel Systemic Therapies

• Second‑generation antiandrogens (abiraterone, enzalutamide, apalutamide, darolutamide).
• PARP inhibitors (olaparib, rucaparib) for patients with DNA‑repair gene mutations.
• Immunotherapy (pembrolizumab) for MSI‑high or high‑tumor‑mutational‑burden disease.

7. Palliative Care & Supportive Measures

• Alpha‑blockers (tamsulosin) or 5‑alpha‑reductase inhibitors (finasteride) for urinary symptoms.
• Pelvic floor muscle training to improve continence after surgery.
• Nutrition counseling—focus on plant‑based, low‑fat diets rich in lycopene (tomatoes) and omega‑3 fatty acids.
• Regular moderate exercise (150 min/week) to maintain cardiovascular health and reduce fatigue.

Prevention Tips

While you cannot change your genetic makeup, several lifestyle and screening strategies can lower the risk of developing a high‑grade prostate cancer:

• Maintain a healthy weight: Obesity is linked to higher Gleason scores; aim for BMI < 25 kg/m².
• Eat a balanced diet: Emphasize fruits, vegetables, whole grains, and lean protein; limit red meat and processed foods.
• Exercise regularly: Aerobic activity and resistance training improve hormone balance.
• Limit alcohol and avoid smoking: Both increase overall cancer risk.
• Stay up to date with screening: Men aged 45–55 with risk factors should discuss PSA testing and DRE with their doctor.
• Consider chemoprevention (if appropriate): Some studies suggest that 5‑alpha‑reductase inhibitors may lower the incidence of high‑grade disease, but discuss risks with a urologist.
• Know your family history: Genetic counseling can identify hereditary cancer syndromes that may warrant earlier or more intensive surveillance.

Emergency Warning Signs

Key Take‑aways

The Gleason score is a cornerstone of prostate‑cancer grading. An abnormal (high) Gleason score signals a more aggressive tumor that may require definitive treatment rather than watchful waiting. Understanding risk factors, recognizing early symptoms, and undergoing appropriate screening can catch high‑grade disease before it spreads. If you notice any warning signs or have concerns about your PSA or family history, reach out to a health‑care professional promptly.

References:

• Mayo Clinic. “Prostate cancer staging.” May 2023.
• National Cancer Institute. “Gleason Score for Prostate Cancer.” 2022.
• American Urological Association. “Guideline for the Management of Clinically Localized Prostate Cancer.” 2024.
• World Health Organization. “Cancer Screening Guidelines.” 2023.
• Cleveland Clinic. “Active Surveillance for Prostate Cancer.” 2023.